Lecanemab for Alzheimer's disease: Discussing risks and benefits is key

by Canadian Medical Association Journal

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Canada recently approved lecanemab to treat early Alzheimer's disease, but the clinical benefits are modest, it carries a risk of serious adverse effects, and treatment is complex. An article in the Canadian Medical Association Journal provides an overview of the medication and advises health care professionals to engage in shared decision-making with patients and caregivers to help them understand the potential risks and benefits.

"The interpretation of benefits from lecanemab may be influenced by the limited availability of therapies for and the personal and societal burdens of Alzheimer's disease. Clinical benefits are modest at best, with uncertain impacts on quality of life, independence and caregiver burden," writes Dr. Sharon Straus, a geriatrician at Unity Health Toronto and professor at the University of Toronto, with co-authors.

Although lecanemab is approved in Canada, it is expensive—about $35,000 to $40,000 per year per patient—and it is not publicly funded. Most provinces and territories remain uncertain about whether they will cover it with health insurance.

Lecanemab treatment is resource-intensive, requiring specialized diagnostics, regular intravenous doses and frequent monitoring with MRI scans. Patients with early Alzheimer's disease and confirmed amyloid in the brain are eligible, with confirmation via a PET scan or a lumbar puncture with cerebrospinal fluid analysis. Brain swelling and small brain bleeds can occur as the drug tries to clear amyloid, the protein that may build up in the brain with Alzheimer's disease.

The authors recommend shared decision-making and provide a tool to help clinicians engage with patients and caregivers.

"Given the uncertain clinical benefit, risks of adverse events, and resource and financial implications, the decision to initiate lecanemab should be individualized. Some patients who place a high value on small potential delays in disease progression may choose to proceed and accept the risks, monitoring requirements and out-of-pocket costs. In some cases, deferring treatment pending further evidence may be a reasonable approach," the authors conclude.

Publication details

Lecanemab use for early Alzheimer disease in Canada, Canadian Medical Association Journal (2026). DOI: 10.1503/cmaj.260193

Journal information: Canadian Medical Association Journal

Key medical concepts

lecanemabAlzheimer's DiseaseMagnetic Resonance Imaging

Clinical categories

Neurology Provided by Canadian Medical Association Journal Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Lecanemab for Alzheimer's disease: Discussing risks and benefits is key (2026, June 29) retrieved 29 June 2026 from https://medicalxpress.com/news/2026-06-lecanemab-alzheimer-disease-discussing-benefits.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.